SecBot SecBot
SECBOTREPLAY Home › Report › FTH

FTH · Faeth Therapeutics reported topline Phase 2 data for PIKTOR…

Faeth Therapeutics, Inc. · 8-K filed Nov 9, 2026 at 08:45 ET

At the news

BULLISHIMPACT 6/10

8-K filed Nov 9, 2026 at 08:45 ET

Faeth Therapeutics reported topline Phase 2 data for PIKTOR (serabelisib + sapanisertib) plus paclitaxel in advanced endometrial cancer, showing a 33% confirmed ORR and preliminary median PFS of 7.4 months in a heavily pre-treated population. The safety profile appears differentiated with low rates of hyperglycemia and stomatitis. The company plans to disclose a registrational trial design by 1H 2027.

  • Confirmed ORR of 33% (12/36) in efficacy-evaluable patients; DCR of 83%
  • Preliminary median PFS of 7.4 months (95% CI 5.3, NR) in all 42 treated patients
  • Preliminary 6-month PFS rate of 62% (95% CI 43, 75)
  • Confirmed ORR of 44% and DCR of 81% among patients with PIK3CA mutation

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access